Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

Broadly neutralizing antibodies are showing promise in the treatment and prevention of HIV-1, with several now being evaluated clinically. Some lead clinical candidates, including antibodies CAP256-VRC26.25, N6, PGT121, and VRC07-523, have one or more N-linked glycosylation sequons in their variable...

Full description

Bibliographic Details
Main Authors: Gwo-Yu Chuang, Mangaiarkarasi Asokan, Vera B. Ivleva, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Rajoshi Chaudhuri, Hui Geng, Bob C. Lin, Mark K. Louder, Krisha McKee, Sijy O’Dell, Hairong Wang, Tongqing Zhou, Nicole A. Doria-Rose, Lisa A. Kueltzo, Q. Paula Lei, John R. Mascola, Peter D. Kwong
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
Antibody engineering
broadly neutralizing antibodies
heterogeneity
HIV-1
n-linked glycosylation
polyreactivity
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1836719

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1836719

Similar Items